Noble Financial Capital Markets Conference
January 17th-20th, 2016
Club Med, South Florida
For the third year in a row, Noble Financial Group will take over all of Club Med's 220 acres to host its "destination" investor conference. NobleCon12, taking place January 17-20, 2016, will feature a lineup that includes 150 presenting companies (most public, with a selection of private companies) who will showcase their innovations, operations and potential to more than 350 qualified investors looking for new investment ideas. Attendees stay onsite at the beautiful Club Med, getting the most out of company presentations, keynote speakers, dynamic panels, social activities and networking. For more information visit www.NobleConference.com
Presenting Companies
Delcath Systems, Inc. (DCTH)
Delcath Systems, Inc. (NASDAQ: DCTH) is a specialty pharmaceutical and medical device company focused on oncology and, more specifically, the treatment of primary and metastatic liver cancers. The company's proprietary product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high dose chemotherapy to the liver while controlling the systemic exposure to those agents. For more information, visit the company's website at www.delcath.com.
Eco-Stim Energy Solutions, Inc. (ESES)
Eco-Stim Energy Solutions, Inc. (NASDAQ: ESES) is an environmentally focused oilfield service and technology company providing well stimulation and completion services and proprietary field management technologies to oil and gas producers drilling in the rapidly expanding international unconventional shale market. EcoStim's proprietary methodology and technology offers the potential to decrease the number of stages stimulated in shale plays through a unique process that predicts high probability production zones while confirming those production zones using the latest generation down-hole diagnostic tools. For more information, visit the company's website at www.ecostim-es.com.
Enumeral Biomedical Holdings, Inc. (ENUM)
Enumeral Biomedical Holdings, Inc. (OTC: ENUM) is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. Enumeral's unique platform allows the identification and characterization of promising new drugs relevant to cancer, infectious and inflammatory diseases, providing for the potential to positively affect millions of patients who are underserved by current therapeutic alternatives. The core technology behind the company's platform was developed at and licensed from the Massachusetts Institute of Technology, Harvard University, Whitehead Institute for Biomedical Research, and Massachusetts General Hospital. For more information, visit the company's website at www.enumeral.com.
Galectin Therapeutics, Inc. (GALT)
Georgia-based Galectin Therapeutics, Inc. (NASDAQ: GALT) is a biotechnology company focused on discovery and development. The company applies its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates are based on its unique carbohydrate technology targeting galectin proteins, which are key mediators of biologic and pathologic function. Galectin is especially pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. For more information, visit the company's website at www.galectintherapeutics.com.
Intellipharmaceutics International, Inc. (IPCI)
Intellipharmaceutics International, Inc. (NASDAQ: IPCI) is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Controlled-release means releasing a drug into the bloodstream or at a target site in the body, over an extended period of time. This type of delivery can enhance efficacy and patient compliance as compared to immediate release formats for the same drug. Hypermatrix technology is the company's propriety product and allows for the intelligent and efficient design of drugs through the precise control of several key variables including varying drug attributes and patient requirements. For more information, visit the company's website at www.intellipharmaceutics.com.
OpGen, Inc. (OPGN)
OpGen, Inc. (NASDAQ: OPGN) is developing and deploying precision medicine tools for antibiotic stewardship management in global healthcare settings, adding real benefits to antimicrobial stewardship programs and assisting clinicians with more rapid information about life threatening infections. Using molecular testing and bioinformatics, OpGen offers a full portfolio of QuickFISH and Acuitas products including the MDRO Gene Test, the Resistome Test, microbial Whole Genome Sequence Analysis, and Acuitas Lighthouse MDRO Management System products. Its QuickFISH products are a suite of FDA-cleared and CE-marked diagnostics for rapid molecular testing of positive blood cultures designed to assure appropriate antibiotic therapy. For more information, visit the company's website at www.opgen.com.
Pure Energy Minerals Ltd. (HMGLF)
Pure Energy Minerals Ltd. (OTC: HMGLF) is a lithium-brine resource developer focused on becoming the lowest-cost lithium supplier for the burgeoning North American lithium battery industry. The company is currently engaged on the development of its prospective Clayton Valley South ("CVS") Lithium Brine Project, a large land position in the southern half of Clayton Valley, Nevada, with excellent existing infrastructure in a first-class mining jurisdiction. The acreage is adjacent to the only producing lithium operation in the United States (Albermarle's Silver Peak lithium brine mine). For more information, visit the company's website at www.pureenergyminerals.com.
RespireRx Pharmaceuticals, Inc. (CORX)
RespireRx Pharmaceuticals, Inc. (OTC: CORX), formerly Cortex Pharmaceuticals, Inc., has multiple drug development programs targeted toward the treatment of brain-related breathing disorders, such as obstructive or central sleep apnea and drug-induced respiratory depression – areas where current treatment options are limited or inadequate. The company's product candidate portfolio includes two clinical stage compounds: dronabinol, which is being developed for obstructive sleep apnea; and CX1739, which is being developed for multiple respiratory indications, including central sleep apnea and drug-induced respiratory depression. For more information, visit the company's website at www.respirerx.com.
